National
United Stand : Serum Institute Of India, Bharat Biotech Bury Differences, Vow To Ensure Smooth COVID-19 Vaccine Distribution
File Picture
Good sense has finally prevailed as the Serum Institute of India (SII) and Bharat Biotech have buried their apparent differences. In a joint statement on behalf of both the companies, they said said they will work together to develop, manufacture and supply the COVID-19 vaccines in India and globally.
SII CEO Adar Poonawalla and Bharat Biotech Chairman and Managing Director Krishna Ella announced their combined intent to develop, manufacture and supply the COVID-19 vaccines for India and the world.
They noted that the most important task in front of them was saving lives and livelihoods in India and globally. Vaccines are global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest. Now that two COVID-19 vaccines have been issued EUA (emergency use authorisation) in India, the focus is on manufacturing, supply and distribution, such that population that need it the most receive high quality, safe and efficacious vaccines, the statement said.
